application. According to Schü ttler and colleagues, 11 the PK parameters for propofol were significantly affected by the mode of administration. The pharmacokinetics and -dynamics (PKPD) of alfentanil and its interaction with propofol has been thoroughly investigated in the 1980s and 1990s. 12 -23 An open TCI system to administer alfentanil is currently available only from one manufacturer using the PK parameter set by Maitre 18 which is based on data from bolus administration collected by several investigators. 12 14 24 19 The parameter set was later validated in 19 surgical patients anaesthetized with nitrous oxide and alfentanil (boluses and variable maintenance infusions). 25 Raemer and colleagues 26 found a bias and an inaccuracy of .50% when using the Maitre 18 parameters to drive a TCI pump in healthy young women and elderly men, whereas bias and inaccuracy was only 21 and 17% with the Scott parameters. 20 They suspected different clearances and administration modes of alfentanil (bolus vs infusion) as possible explanation for this difference. Barvais and colleagues 27 administered alfentanil as infusion with different rates, took venous blood samples and developed a population and individual twocompartment models for alfentanil kinetics. Compared with infusion data, they found a higher elimination clearance and a higher performance error in data where a large bolus was rapidly applied. Mertens and colleagues 28 showed that propofol significantly reduces the clearance of alfentanil especially during induction. Masui and colleagues 3 have compared different PKPD models for propofol using bolus, infusion and TCI data. A comparable study is not available for opioids. We postulate that an optimal parameter set should not be affected by the mode of drug application (bolus or infusion) and should allow predictions of the plasma concentration with a performance error of ≤30% 29 and a bias within +20%. 3 For safety reasons overprediction of the concentration rather than underprediction would be preferable for an opioid. 30 The aim of this study was to compare the performance of previously published PK models for alfentanil and to determine which of the different models is most appropriate for use in TCI and anaesthesia drug display systems according to previously defined criteria. We used two data sets from the department of anaesthesia of the Bern University Hospital. Alfentanil was administered by TCI 31 and as repeated single bolus doses (unpublished data), respectively.
Methods
For this investigation, we retrospectively analysed the measured alfentanil plasma concentration and recorded dosing histories of two previously performed clinical studies. 31 In the first study 31 (data set I, 'I' for infusion data), 30 patients undergoing orthopaedic surgery were randomly allocated to anaesthesia with 70 vol.% of xenon or 70 vol.% of nitrous oxide plus 2 vol.% of desflurane. Alfentanil was administered by TCI (Stanpump programme, S.L.
Shafer, MD., Palo Alto, CA, USA) using the parameter set by Shafer (as integrated in Stanpump) with target concentrations between 5 and 400 ng ml 21 . Arterial blood samples were obtained at baseline, before and after skin incision, before and after each change of the target concentration, after pump stop, and hourly in the recovery room for 3 h. In the second study (unpublished, data set B, 'B' for bolus data), 40 patients undergoing orthopaedic surgery were anaesthetized with propofol TCI (plasma target mode) using the parameter set by Schnider and colleagues 32 and alfentanil administered as i.v. boli of 0.5-1.0 mg using an ASENA GH infusion pump (Carefusion Corporation, San Diego, CA, USA) which was connected to a laptop computer for recording of the dosing history. Arterial blood samples were obtained at baseline, before and after tracheal intubation, after skin incision, at the end of surgery, before pump stop, and after extubation. For both studies approval from the ethics committee had been obtained and the patients gave their written informed consent (reference code: KEK Bern 156-97 and KEK Bern 82-06, respectively). In all patients, the arterial blood samples were centrifuged immediately after the end of the case and the supernatant was stored at 2268C. The plasma concentrations were measured by gas chromatography mass spectrometry with a lower detection limit of 2 ng ml 21 .
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The alfentanil dosing histories from the two studies (data set I and B) were used as input to calculate predicted plasma concentrations over time based on eight different PK parameter sets using the PKPD Tools for Excel by Minto and Schnider (PKPD Tools is freely available on the internet at www.pkpdtools. com). The following parameter sets were compared: Scott and Stanski, 20 Scott and Stanski weight adjusted (as integrated in Stanpump), Maitre, 18 Shafer (as integrated in Stanpump),
Hudson, 16 Mertens, 28 Fragen, 15 and Lemmens 17 ( Tables 1-3) .
For every blood sample, the measured and the predicted alfentanil plasma concentrations were used to calculate the performance error of the different models according to Varvel and colleagues 30 (equation 1).
where PE¼performance error (%), Cm¼measured concentration, Cp¼predicted concentration, i¼patient number and j¼blood sample number in patient i. The median absolute performance error (MDAPE i ) and the median performance error (MDPE i ) were determined for each patient according to the following equations 2 and 3:
where MDAPE i represents the accuracy and MDPE i the bias of patient i with j¼1,. . .,N i blood samples. Population estimates
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were calculated according to equations 4 and 5 (two-stage approach).
30
MDAPE (accuracy) = Median{MDAPE i , i = 1, ..., M}, (4)
where MDAPE represents the population accuracy and MDPE represents the population bias of i¼1,. . ., M patients. Wobble representing the variation of the performance error around MDPE and Divergence representing the expected time related changes in performance were calculated according to the following equations 6 and 7:
where Wobble i and Divergence i are the estimates for patient i with j¼1,. . .,N i blood samples and t ij is the time in min that the corresponding PE ij was determined. Population estimates were calculated similar to those of MDAPE and MDPE (equations 4 and 5). For comparison, the recently proposed logarithmic indices for accuracy and bias described by Masui and colleagues 3 were calculated as well using the following equations 8 and 9:
where Accuracy i and Bias i are the estimates for patient i with j¼1,. . .,N i blood samples. Population estimates were calculated by analogy with the population estimates of MDAPE and MDPE (equations 4 and 5).
We defined an optimal parameter set for use in TCI and display systems as follows: It should be unaffected by the mode of administration (bolus vs infusion), the MDAPE (accuracy) should be ≤30% 29 and the MDPE (bias) should be within +20%. (6) 74 (12) 74 (6) 75 (14) 71 (14) 74 (11) Height (cm) n.a. n.a. 165 (7) n.a. 182 (7) n.a. 172 (9) 172 (9 Optimal alfentanil pharmacokinetic parameter set 
Results
The data from 30 patients (infusion) and 40 patients (bolus) were included. The characteristics of the study populations are presented in Group I and 20 of 40 in Group B were ASA physical status I, the remainder was ASA II (P¼0.003). The time course of the plasma concentrations in two typical patients of our study groups is presented in Figure 1 . A total of 850 blood samples were analysed, 649 in the infusion and 201 in the bolus study, respectively. All blood samples could be included in the analysis.
MDAPE and log accuracy
The median MDAPE and log accuracy in both populations was within the limits of acceptance with the parameter sets by Scott, 20 Fragen, 15 and Scott weight adjusted, whereas it was outside with the others (Fig. 2) . In the infusion data (green boxes in Fig. 2 ), the MDAPE with the Scott parameters was significantly lower than with the parameters by Hudson, 16 Mertens, 28 Lemmens, 17 and Shafer (P,0.05). MDAPE values were 22.3% (Scott), 20 26 .5% (Fragen), 15 26 .5% (Scott weight adjusted), and 41% (Maitre) . 18 The log accuracy was significantly lower compared with Hudson, 16 Lemmens, 17 and Shafer (P,0.05).
In the bolus data (orange boxes in Fig. 2) , the MDAPE and log accuracy of the parameter sets by Scott, 20 Fragen, 15 In the parameter sets by Maitre 18 and Lemmens, 17 the MDAPE was higher when alfentanil was administered as infusion compared with bolus administration; whereas in the log accuracy this difference was significant with the parameters by Lemmens 17 (P,0.003). This was reflected by the multiple pairwise comparisons between the different parameter sets, which yielded different results when alfentanil was administered as multiple boluses or as infusion (as mentioned above). None of the performance indices inside the Group I were affected by the different co-administered hypnotic drugs (desflurane plus nitrous oxide or xenon, P≥0.361).
The detailed results of the multiple pair-wise comparisons of all the parameter sets are presented in Figure 2 .
MDPE and log bias
The parameter set by Fragen 15 was selected as control because MDPE and log bias were optimally within the acceptable range (Fig. 3) . The median MDPE and log bias in the study populations were within or very close to the acceptable limits (+20% or +0.1) with the parameters by Fragen, 15 Scott, 20 and Scott weight adjusted, whereas the others were all significantly different from control (Fig. 3) . In both data sets MDPE and log bias of the parameter sets of Scott, 20 Scott weight adjusted and Shafer showed tendency to overpredict whereas those of Maitre, 18 Hudson, 16 and Mertens 28 showed tendency to underpredict the measured concentration (Fig. 3) . 18 with the bolus data. As MDAPE and log accuracy also MDPE and log bias were affected by the mode of administration (infusion or bolus) with the parameters by Maitre, 18 but not Lemmens (P,0.001). 17 None of the performance indices inside the Group I were affected by the different co-administered hypnotic drugs (desflurane plus nitrous oxide or xenon, P≥0.263). The detailed results of the multiple pair-wise comparisons of the different parameter sets are presented in Figure 3 .
Wobble and divergence
In both populations, the variation of the PE around the MDPE (Wobble) in the Scott parameters (weight adjusted or not) was lower compared with those by Hudson, 16 Mertens, 28 Lemmens, 17 and Maitre. 18 The Wobble was also affected by the mode of administration with the parameters by Scott, 20 Fragen, 15 Maitre, 18 and Mertens. 28 Further details are reported in Figure 4 . In both populations, the Divergence was +5% or less in the parameters by Scott (weight adjusted or not), Fragen, 15 Optimal alfentanil pharmacokinetic parameter set Maitre, 18 Lemmens, 17 and Mertens. 28 In the infusion group, the median (inter-quartile range) of the Divergence (% h 21 )
for the Hudson 16 and Shafer parameters was 12 (0.8, 45) and 9 (7, 12), respectively. In bolus application, the Divergence values were 18 (2, 31) and 7 (5, 10), respectively (Fig. 4) .
Discussion
The previously defined criteria for an optimal parameter set (being unaffected by mode of administration, MDAPE (accuracy) ≤30% and MDPE (bias) within (+20%) were met by the Scott 20 (original and weight adjusted version) and the study population was very small the data did not allow estimating the parameters for the third compartment.
The Maitre parameter set 25 was developed from pooled bolus data from Bovill, 12 Camu, 14 Helmers, 24 and Schü ttler 19 forming a representative study population with a large number of blood samples allowing to estimate the effect of age, sex and weight as covariates. With our data from repeated bolus application it performed as good as Scott 20 but was significantly inferior with the infusion data. The reason may be the higher elimination clearance of the Maitre parameters. 27 A comparable performance with similar differences regarding bolus and infusion application could be observed with the parameter set by Lemmens. Mertens and colleagues 28 described the PK interaction between alfentanil and propofol in healthy volunteers. A propofol Cp of 1.5 mg ml 21 reduced the Clearances 1, 2 and 3 by 15, 300 and 50%, respectively, which was attributed to a reduced hepatic blood flow because of the propofol induced vasodilatation. Because propofol and alfentanil both are bound to lung tissue (first pass effect) the alfentanil concentrations after the initial bolus of alfentanil were higher than expected in the presence of propofol. The population studied by Mertens and colleagues 28 is not representative for the patient population undergoing surgery. This may explain why the performance of the Mertens parameter set was inferior to others even in our data set where propofol was co-administered. The intra-individual variation of the prediction error (Wobble) was higher when alfentanil was administered as boluses in most of the parameter sets. In the bolus data, it was lower in the Scott 20 than in the Maitre 25 parameters.
The variation of the performance error over time (Divergence) was highest in the Hudson 16 parameters, probably because they were determined in cardiovascular high risk patients, which is a different population compared with our patients. The elimination clearance estimated by Hudson 16 is higher compared with parameter sets that were more stable over time. The lowest Divergence had the Scott 20 parameters, expressing the higher ability to produce stable plasma concentrations of this set compared with other sets, which can be seen as advantage for titration of analgesia in clinical use. Fragen's 15 negative Divergence values in both data sets mean that the performance error was higher at the beginning of the infusion. Our results obtained in 70 patients with a total of 850 blood samples are consistent with those of Barvais and colleagues 27 obtained in eight volunteers and with those of Raemer and colleagues 26 obtained in 29 healthy women and 22 older men. They also confirm that the application mode may affect the prediction error of PK parameters. 26 27 In an earlier study on 25 patients where alfentanil was administered as TCI during surgery and for postoperative pain control 34 the MDAPE of the Scott parameters 20 was similar to the parameters by Lemmens 17 and Maitre. 18 The blood samples in that study 34 were obtained only in the postoperative study period where the subjects were closer to a PK pseudo-steady state. In the late phase of drug administration, the inaccuracy related to the volume of the central compartment (volume 1) which is 3-fold larger in the Maitre set, is less important than at the beginning. This may explain the different result compared with previous studies 26 27 and our data.
Perus and colleagues 35 recently evaluated the predictive performance of the Maitre 25 and the Scott 20 parameters in 10 obese and 6 non-obese women anaesthetized with desflurane after a propofol induction. During drug infusion, the Scott parameters were superior to the Maitre parameters in the non-obese controls, while they were similar in the obese. Conversely, the decay after infusion stop was better predicted by the Maitre parameters in both patient groups. As our study populations were non-obese, these results are consistent with ours. None of the investigated parameter sets is perfect. Particularly, the initial phase of drug administration and the terminal phase of drug elimination are not well predicted. Most authors of the previous studies concluded that further studies are necessary. Because of the high costs and the Optimal alfentanil pharmacokinetic parameter set lack of clinical relevance in the absence of open TCI systems or anaesthesia display systems in the past, they have not been performed yet. It is even uncertain if larger studies would yield better parameter sets at all. Some arguments supporting this statement can be found in the paper by Schnider and colleagues 32 reporting the propofol PK parameter set. Beside developing a new PKPD parameter set the purpose of the study was to prove that adding ethylenediaminetetraacetate (EDTA) to the previous propofol formula does not change PKs. Therefore, each patient was examined twice, once with and once without EDTA admixture to propofol. As the PKPD parameters were identical between the two formulas the individual difference of the predicted plasma propofol concentrations in the two study sessions gives important information on the intra-individual prediction error. ance error of alfentanil despite individual tailoring of PK parameters. This means that the individual PK parameter set may change from one study session to another, which would appear as random effect in the modelling process. The prediction error of a population is very unlikely better than the prediction error in an individual subject. Volume 1 and clearance 1 are the most important parameters to define the initial bolus and maintenance infusion. By individual post hoc Bayesian corrections of these two parameters according to one measurement of the plasma alfentanil concentration, the prediction error of the individualized parameters was improved in some patients but not in others. 37 The mean absolute performance error in the population did therefore not change but its standard deviation decreased. Interestingly, adding more than one measurement of the plasma concentration did not further improve the performance error. 3 therefore, proposed the logarithmic accuracy and bias, respectively (equations 8 and 9), which are not affected by the direction of the deviation (overprediction vs underprediction). Although there are some differences in the statistic pair-wise comparison between log accuracy and MDAPE and log bias and MDPE, respectively, the conclusions drawn from the different performance parameters are similar. There are certainly some limitations in our study: the number and timing of blood samples are not balanced in the two data sets. It was not the intention of the two studies from where the data were used, to evaluate or even develop a new PK parameter set for alfentanil but only to control potential prediction errors of the used model. We cannot exclude that this may have affected the precision of MDAPE and MDPE in the bolus data set. Because the blood samples were obtained in the flat part of the concentration-time curve and not during the peaks the performance error of the predicted plasma concentrations are unlikely to be biased. The two study groups did not differ in gender distribution, but the patients of the bolus group were significantly older and 50% were ASA physical status II (compared with 13% in the infusion group). The reasons were obesity, hypertension, smoking of .20 pack years, diabetes, exercise asthma and clinically insignificant liver disease. It is very unlikely that these co-morbidities that were not associated with clinical symptoms in normal daily life would have substantially affected PKs of alfentanil.
The two groups also differed in the type of hypnotic drug (propofol in the bolus group vs xenon or nitrous oxide plus desflurane in the infusion group). It is not very likely however, that the propofol effect on alfentanil PKs as reported by Mertens 28 was the dominating reason for the difference seen in some parameter sets because the performance of the Mertens parameters was substantially inferior to the Scott parameters. Within Group I, there was no difference in the parameter sets' performance between patients receiving xenon and those receiving nitrous oxide plus desflurane.
Conclusion
In healthy orthopaedic patients, the PK parameters by Scott and Maitre were equally valid when alfentanil was given as repeated boluses. When given as infusion, the Maitre parameters were less accurate and subject to a significant bias. We cannot exclude that the difference between bolus and infusion is partially because of the different hypnotics used.
